Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

The selective estrogen receptor modulator (SERM) tamoxifen has long been used to treat both early and advanced breast cancer. Raloxifene is a second-generation SERM that, in addition to combatting osteoporosis, may also lessen the risk of invasive breast cancer in postmenopausal women. The National Surgical Adjuvant Breast and Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR) is a prospective, randomized, double-blind trial...